GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.

Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Online weight-loss company Noom said on Monday it would sell copies of Novo Nordisk's Wegovy at an introductory price of $119 for up to a quarter of the branded drug's standard dose, giving patients a ...